Zeist, Netherlands

Riemke Van Dijkhuizen

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Riemke Van Dijkhuizen: Innovator in Human Antibodies**

Introduction

Riemke Van Dijkhuizen, located in Zeist, Netherlands, is a notable inventor known for his contributions to the field of biotechnology. With a focus on human monoclonal antibodies, he has made significant strides in therapeutic and diagnostic applications.

Latest Patents

Riemke holds a patent titled "Human antibodies and antibody-drug conjugates against CD74." This patent discloses isolated human monoclonal antibodies that bind to human CD74, along with related antibody-drug conjugates. Furthermore, it details pharmaceutical compositions that comprise these antibodies or antibody-drug conjugates and outlines various therapeutic and diagnostic methods for their use.

Career Highlights

Currently, Riemke works at Genmab AS, a leading biotechnology company that specializes in the innovation and development of differentiated antibody therapeutics for the treatment of cancer. His work contributes to advancing medical treatments that can improve patient outcomes.

Collaborations

Throughout his career, Riemke has worked alongside talented colleagues, including Sandra Verploegen and Marije Overdijk. Collaborating with such professionals fosters a rich environment for innovation and enhances the potential for breakthrough discoveries in antibody therapies.

Conclusion

Riemke Van Dijkhuizen stands out as an inventive force in the realm of human antibodies, contributing to important advancements in the medical field. His work at Genmab AS, combined with his patent achievements, reflects his commitment to improving therapeutic options and diagnostic methods for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…